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ABSTRACT: Pseudoachondroplasia (PSACH) and mul-
tiple epiphyseal dysplasia (MED) are relatively common
skeletal dysplasias resulting in short-limbed dwarﬁsm,
joint pain, and stiffness. PSACH and the largest propor-
tionofautosomaldominantMED(AD-MED)resultsfrom
mutations in cartilage oligomeric matrix protein (COMP);
however, AD-MED is genetically heterogenous and can
also result from mutations in matrilin-3 (MATN3)a n d
type IX collagen (COL9A1, COL9A2,a n dCOL9A3).
In contrast, autosomal recessive MED (rMED) appears
to result exclusively from mutations in sulphate trans-
porter solute carrier family 26 (SLC26A2). The diagnosis
of PSACH and MED can be difﬁcult for the nonexpert
due to various complications and similarities with other
related diseases and often mutation analysis is requested
to either conﬁrm or exclude the diagnosis. Since 2003, the
European Skeletal Dysplasia Network (ESDN) has used
an on-line review system to efﬁciently diagnose cases re-
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ferred to the network prior to mutation analysis. In this
study, we present the molecular ﬁndings in 130 patients
referred to ESDN, which includes the identiﬁcation of
novel and recurrent mutations in over 100 patients. Fur-
thermore, this study provides the ﬁrst indication of the
relative contribution of each gene and conﬁrms that they
account for the majority of PSACH and MED.
Hum Mutat 33:144–157, 2012. C  2011 Wiley Periodicals, Inc.
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Introduction
Pseudoachondroplasia (PSACH; MIM# 177170) and multiple
epiphyseal dysplasia (MED; MIM# 132400) are relatively common
skeletal dysplasias that can be inherited as either autosomal domi-
nant(PSACHandAD-MED)orrecessive(AR-MED;rMED)condi-
tions [Briggs and Chapman, 2002; Superti-Furga and Unger, 2007].
PSACH usually manifests in the second year of life and is char-
acterized by moderate to severe disproportionate short stature, lig-
amentous laxity, and degenerative joint disease. MED is a clini-
cally variable disease that manifests in early-to-mid childhood with
joint pain and stiffness, mild to moderate short stature, and early
onset osteoarthritis [Barrie et al., 1958; Fairbank, 1947; Rimoin
et al., 1994]. At least one other disorder overlaps phenotypically
with MED; familial hip dysplasia (Beukes type; MIM# 142669)
[Cilliers and Beighton, 1990], which is mapped to chromosome
4q35 [Roby et al., 1999] and has been grouped with AD-MED in
C   2011 WILEY PERIODICALS, INC.the 2010 revision of the “International Nosology and Classiﬁcation
of Genetic Skeletal Disorders” [Warman et al., 2011].
PSACH is believed to result exclusively from mutations in the
gene encoding cartilage oligomeric matrix protein (COMP;M I M #
600310), as does the largest proportion of AD-MED [Briggs and
Chapman, 2002; Briggs et al., 1995; Hecht et al., 1995]. Presumed
autosomal recessive forms of PSACH [Dennis and Renton, 1975;
Wynne-Davies et al., 1986; Young and Moore, 1985] were proposed
to be caused by germline mosaicism and this has been proven by
COMP analysis [Ferguson et al., 1997; Hall et al., 1987]. However,
a disorder resembling PSACH without a COMP mutation has been
described[Sprangeretal.,2005],butthegeneticbasisofthisPSACH
variant remains undetermined.
AD-MED is a much more heterogeneous disorder, both at the
phenotypic and genetic levels. In addition to COMP mutations, it
can also result from mutations in the genes encoding matrilin-3
(MATN3, EDM5; MIM# 607078) and type IX collagen (COL9A1,
EDM6; MIM# 120210; COL9A2, EDM2; MIM# 600204; COL9A3,
EDM3; MIM# 600969, respectively) [Briggs and Chapman, 2002;
Chapmanetal.,2001;Czarny-Ratajczaketal.,2001;Muragakietal.,
1996; Paassilta et al., 1999; Unger et al., 2008]. Furthermore, several
studies have suggested that a variable proportion of AD-MED can
resultfrommutationsinothergenes[Jakkulaetal.,2005;Zankletal.,
2007],buttheidentitiesofthesegeneshavenotyetbeendetermined.
AR-MED(rMED)canresultfromhomozygosityorcompoundhet-
erozygosity for mutations in the gene encoding SLC26A2 (EDM4;
MIM# 226900) [Hastbacka et al., 1999; Rossi and Superti-Furga,
2001; Superti-Furga et al., 1999] and is the mild end of the pheno-
typic spectrum that includes achondrogenesis 1B and diastrophic
dysplasia [Rossi and Superi-Furga, 2001].
TheextensivegeneticheterogeneityofMEDcombinedwithwide-
ranging clinical variability, including both intra- and interfamilial
variability, and various complications such as osteochondritis dis-
secans and mild myopathy provide a diagnostic challenge for the
nonexpert [Makitie et al., 2004; Newman et al., 2000; Unger, 2002;
Unger et al., 2008; Zankl et al., 2007]. In order to better understand
the molecular genetics of MED, we screened for COMP, COL9A1,
COL9A2,COL9A3,MATN3,andSLC26A2mutationsinover100pa-
tients referred to the European Skeletal Dysplasia Network (ESDN)
via the on-line case manager (www.ESDN.org). In many of these
patients, a clinical diagnosis of PSACH or MED was conﬁrmed
(or suspected) by the expert panel of the ESDN prior to mutation
screening.However,wealsoincludedacohortofpatients,whichthe
expert panel felt were not classical examples of these diseases due to
a variety of unusual clinical and/or radiographic features (detailed
in Supp. Table S1). Indeed, in many of these cases an alternative
diagnosis was suggested prior to mutation screening. However, the
inclusionofthesepatientswasimportantforidentifyingphenotypic
outliersofthe“classical”PSACHandMEDdiseasespectrumandto
also identify speciﬁc radiographic and/or clinical features that are
generally uncharacteristic of molecularly conﬁrmed MED.
Materials and Methods
All cases were submitted on-line via the secure case manager site
(https://cm.esdn.org/). Every case was then reviewed and discussed
by the ESDN panel members. Following discussion, DNA sam-
ples from the patient, and when available affected and unaffected
family members, were sent for mutation screening in Manchester
(for PSACH and AD-MED) or Lausanne (AR-MED). Screening of
COMP (exons 8–19), MATN3 (exon 3), and the type IX collagen
genes (only the exon sequence and splice donor/acceptor sites of
exon 8 of COL9A1 and exon 3 of COL9A2 and COL9A3) was per-
formed as previously described [Jackson et al., 2004; Kennedy et al.,
2005a; Zankl et al., 2007]. This screening protocol reﬂected our
current knowledge of all known locations of PSACH and AD-MED
mutations in the type III repeat and C-terminal regions of COMP,
the A-domain of MATN3,a n dt h eC O L 3d o m a i no ft y p eI Xc o l l a -
gen. Screening of SLC26A2 was performed as previously described
[Rossi and Superti-Furga, 2001]. All mutations were conﬁrmed in
a second PCR reaction. Primer sequences and PCR conditions for
exons 1–7 of COMP,e x o n s3 – 6o fMATN3, exons 1–3 and 5–6 of
MATN1,e x o n s2 ,6 +7o fMATN4, and exon 50 of COL2A1 are pre-
sented in Supp. Table S2. These exons encode important structural
and/or functional domains in COMP (type II EGF-like repeats),
MATN3(EGF-likerepeats),matrilin-1(A-domains),matrilin-4(A-
domains), and type II collagen (triple-helical region).
Proofofpathogenicitywasdeﬁnedbyoneormoreofthefollowing
criteria; (1) a previously published mutation with co-segregation in
a family and/or absent in controls, (2) a de novo mutation or co-
segregationinthisstudy,(3)alterationofanevolutionaryconserved
knownfunctionalresidueineithertheN-typemotiforC-typemotif
of the type III repeat region of COMP or the A-domain of MATN3,
(4) biochemical evidence of a pathogenetic affect.
Results
As part of this 7-year study (2003–2010), we screened DNA from
28 PSACH patients for mutations in COMP, 77 patients (suspected
AD-MED and variants) for mutations in COMP, MATN3,a n dt h e
threetypeIXcollagengenes(COL9A1,COL9A2,andCOL9A3),and
22 patients for mutations in SLC26A2 (suspected rMED).
Mutation Analysis of COMP in Suspected PSACH
COMP is a modular protein comprising an amino-terminal
coiled-coil oligomerization domain, four type II (EGF-like) do-
mains,seventypeIII(CaM-like)repeats,andaC-terminalglobular
domain (CTD).
WeidentiﬁedtypeIIIrepeatregionCOMPmutationsin27ofthe
28 patients with PSACH (>96%; Table 1; Fig. 1), which were dis-
tributedbetweensevenexons(exons9,10,11,13,14,16,and18)and
comprised missensemutations (67%) or small deletions (30%) and
deletions/insertions(3%).WedidnotidentifyanyPSACHmissense
mutations in exons 8, 12, 15, 17, or 19 of COMP, which is consis-
tent with our previous ﬁndings [Kennedy et al., 2005a] (Fig. 1),
although thebiological signiﬁcance ofthis observation remainsun-
known. Ten of the mutations (37%) were novel while the common
p.Asp473del mutation was identiﬁed in six patients (22%). The
CTD mutations p.Thr529Ile, pGly719Ser, and p.Thr585Arg, which
weandothershavepreviouslydescribed[Briggsetal.,1998;Jakkula
et al., 2003; Kennedy et al., 2005b], were identiﬁed in four pa-
tients thus conﬁrming the clustering of the CTD mutations into
distinct regions [Kennedy et al., 2005b]. We also screenedCOMP in
three patients with atypical PSACH but did not identify a mutation
(Table 2; Fig. 2).
Mutation Analysis of COMP, MATN3, and the Type IX
Collagen Genes in Suspected AD MED
We identiﬁed COMP m u t a t i o n si n3 7p a t i e n t sw i t hM E D
(Table 3), which were distributed between nine exons (exons 8–
14, 16, and 18) and comprised missense mutations (>86%), small
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Patient/family
Diagnosis on
referrala
Diagnosis following
reviewb Exon DNA change Protein change
COMP
domain Published and/or proof of pathogenicity
ESDN-00814 PSACH PSACH 9 c.869A>G p.Asp290Gly T3 Related mutation p.Asp290Asn shown to
be de novo in Ikegawa et al. [1998]
ESDN-00877 PSACH PSACH 9 c.895G>C p.Gly299Arg T3 Ikegawa et al. [1998] (absent in controls)
ESDN-00385 PSACH PSACH 10 c.976G>T p.Asp326Tyr T3 de novo mutation in this family and
conserved functional residue in
C-type motif
ESDN-00622 PSACH PSACH 10 c.1021_1026del p.Glu341_Asp342del T3 Kennedy et al. [2005a] and de novo
mutation in this family
ESDN-00155 PSACH n/d 10 c.1048_1116del p.Asn350_Asp372del T3 de novo mutation in this family and
deletion of conserved functional
residues in C- and N-type motifs
ESDN-00966 PSACH PSACH 10 c.1133A>T p.Asp378Val T3 de novo mutation in this family
ESDN-00672 MED
Fairbank
PSACH 11 c.1159T>C p.Cys387Arg T3 Conserved functional residue in C-type
motif
ESDN-01201 PSACH PSACH 11 c.1205_1212delinsTCTGT p.Gly402_Gly404delinsValCys T3 Deletion of conserved functional
residues in C-type motif
ESDN-00197 PSACH PSACH 13 c.1318G>A p.Gly440Arg T3 Loughlin et al. [1998] (absent in
controls)
ESDN-00294 SMD PSACH 13 c.1336G>A p.Asp446Asn T3 Maddox et al. [1997] (absent in controls)
a n dd en o v om u t a t i o ni nt h i sf a m i l y
ESDN-01016 No diagnosis PSACH 13 c.1343G>C p.Cys448Ser T3 Conserved functional residue in C-type
motif
ESDN-00165 PSACH PSACH 13 c.1417_1419del p.Asp473del T3 Hecht et al. [1995] (common mutation)
ESDN-00166 PSACH PSACH 13 c.1417_1419del p.Asp473del T3 Hecht et al. [1995] (common mutation)
ESDN-00449 PSACH PSACH 13 c.1417_1419del p.Asp473del T3 Hecht et al. [1995] (common mutation)
ESDN-00658 PSACH PSACH 13 c.1417_1419del p.Asp473del T3 Hecht et al. [1995] (common mutation)
ESDN-00724 PSACH PSACH 13 c.1417_1419del p.Asp473del T3 Hecht et al. [1995] (common mutation)
ESDN-01015 PSACH PSACH 13 c.1417_1419del p.Asp473del T3 Hecht et al. [1995] (common mutation)
ESDN-00242 PSACH PSACH 13 c.1417G>C p.Asp473His T3 Conserved functional residue in C-type
motif
ESDN-00020 PSACH PSACH 13 c.1423G>A p.Asp475Asn T3 Deere et al. [1998] (absent in controls)
and conserved functional residue in
C-type motif
ESDN-00248 PSACH PSACH 13 c.1445A>G p.Asp482Gly T3 Susic et al. [1998] and conserved
functional residue in C-type motif
ESDN-00204 PSACH PSACH 14 c.1520A>G p.Asp507Gly T3 Deere et al. [1998] (absent in controls)
and conserved functional residue
ESDN-00490 PSACH PSACH 14 c.1532A>G p.Asp511Gly T3 Conserved functional residue in C-type
motif
ESDN-01203 No diagnosis PSACH 14 c.1544A>G p.Asp515Gly T3 de novo mutation in this family
ESDN-00034 PSACH PSACH 14 c.1586C>T p.Thr529Ile CTD Kennedy et al. [2005a,b] (absent in
controls)
ESDN-00575 PSACH PSACH 14 c.1586C>T p.Thr529Ile CTD Kennedy et al. [2005a,b] (absent in
controls)
ESDN-00109 PSACH Mild PSACH or MED 16 c.1754C>G p.Thr585Arg CTD Briggs et al. [1998] (family studies)
ESDN-00894 PSACH PSACH 18 c.2155G>A p.Gly719Ser CTD Kennedy et al. [2005a,b] (absent in
controls)
aDiagnosis as provided by the referring clinician.
bConsensus reached by the ESDN panel after review.
Proof of pathogenicity is deﬁned by one or more of the following criteria; (1) a previously published mutation with family studies or absent in controls (indicated by
parenthesis), (2) a de novo mutation or co-segregation in this study, (3) alteration of an evolutionary conserved functional residue in either the N-type motif or C-type motif of
the type III repeat region of COMP. Nucleotide numbering according to cDNA sequence with GenBank accession number NM_000095.2. Nucleotide 1 has been c o u n t e da st h e
ﬁrst nucleotide of the translation initiation codon.
PSACH, pseudoachondroplasia; MED, multiple epiphyseal dysplasia; SMD, spondylometaphyseal dysplasia; T3, type 3 repeat region of COMP; CTD, C-terminal domain of
COMP; n/d, diagnosis not discussed by ESDN.
in-frame deletions (∼5%), duplications (∼5%), insertions (<3%),
and deletion/insertions (<3%). We did not identify any MED mis-
sensemutationsinCOMPexons15,17,and19,whichareagaincon-
sistent with our previous ﬁndings [Kennedy et al., 2005a] (Fig. 1).
Fifteen (∼40%) of the mutations were novel, while the recurrent
mutations p.Asp385Asn, p.Asn523Lys, and p.Arg718Pro/Trp were
each identiﬁed in three patients [Ballo et al., 1997; Kennedy et al.,
2005b; Mabuchi et al., 2003]. Interestingly, MED patient ESDN-
00594 was found to have two potential COMP missense mutations;
p.Gly501Asp in the Type III-repeat region and p.Gln756Arg in the
CTD (Table 3).
MATN3 mutations were identiﬁed in 13 MED patients and com-
prised predominantly of missense mutations (∼92%) and a novel
in-frame deletion, all within exon 2 encoding the single A-domain
of MATN3 (Table 3). Nine mutations affected residues forming
the internal β-sheet of the A-domain (i.e., βB, βD, βE, and βF),
while four mutations affected residues in one of the six external
α-helices (i.e., α4, α5, or α6) [Fresquet et al., 2007]. The recurrent
mutations p.Thr120Met and p.Arg121Trp [Cotterill et al., 2005;
Jackson et al., 2004] were each identiﬁed in more than one patient.
We also identiﬁed an in-frame deletion/insertion (c.513_530del),
which is predicted to result in a p.Asp171_Glu177delinsGlu in a
single family with MED. MED patient ESDN-00594, who had pre-
viously tested heterozygous for p.Gly501Asp and p.Gln756Arg in
COMP, was also shown to be heterozygous for p.Val245Met in
MATN3 (Tables 3 and 4).
146 HUMAN MUTATION, Vol. 33, No. 1, 144–157, 2012Figure 1. Exon distribution of COMP missense mutations in PSACH
andMED.ThecumulativedistributionofCOMPmissensemutationsfrom
this study and that published by Kennedy et al. [2005a] is represented
graphically. The total number of patients reported in these two studies
is86(n=35PSACH;n=51MED)andthesedataclearlyshowthatexons
10 and 11 are enriched for MED missense mutations, while missense
mutations in exon 13 mostly cause PSACH. In these two studies, we
identiﬁednoCOMPmissensemutationsinexons15(aa557–572),17(aa
639–696),and 19(aa743–757)and only asingleMEDmissensemutation
in exon 12.
Finally, we identiﬁed COL9A2 mutations in ﬁve MED patients
and a COL9A3 mutation in a single MED patient (Table 3). The
COL9A2 mutations that we identiﬁed were all in the splice donor
site of exon 3 and were therefore consistent with previous ﬁndings
[Fiedler et al., 2002; Holden et al., 1999; Muragaki et al., 1996]. In
our cohort of patients, mutations were identiﬁed at positions +3,
+5, and +7 of the splice donor consensus sequence (i.e.,
+1CCG
gtgagt
+9) and are therefore consistent with those previously
identiﬁed, with just one exception. MED patient ESDN-01003 was
heterozygousforc.186+4a>c(i.e., +7inconsensussequence),which
hasnotbeenpreviouslydescribed.Wedidnotdirectlyassaywhether
this speciﬁc mutation would affect splicing, but the patient tested
mutationnegativeforCOMP,MATN3,COL9A1,andCOL9A3,and
the c.186+4a>c mutation co-segregated with the affected mother
and brother of the proband.
Twopatientshadtherelativelycommonc.186+2t>cchange,which
has previously been reported in several families of European origin
[Muragaki et al., 1996]. We also identiﬁed a c.148-2a>g mutation in
intron2ofCOL9A3inESDN-00986.Althoughthisspeciﬁcsequence
change has not been previously published, a c.148-2a>t mutation
has been shown to be pathogenic and to result in the skipping of
exon 3 of COL9A3 due to the loss of the consensus “a” at the –2
position of a splice acceptor site [Paassilta et al., 1999].
In summary, we identiﬁed mutations in 27 patients with PSACH
and56patientswithAD-MED.TheMEDmutationsthatweidenti-
ﬁed in our patient cohort were found in the COMP (66%), MATN3
(24%), COL9A2 (8%), and COL9A3 (2%) genes. We did not iden-
tify a COL9A1 mutation in any patient sample analyzed. These data
conﬁrm recent studies showing that COMP mutations are the pre-
dominant cause of MED [Zankl et al., 2007], while type IX collagen
gene mutations account for only about 10% of the currently known
mutations in AD-MED.
Mutation Analysis of SLC26A2 in AR-MED (rMED)
We screened 22 patients for mutations in SLC26A2 that had a
diagnosis consistent with AR-MED as determined by the ESDN
expert panel. Sixteen (16/22, ∼73%) of these patients were either
homozygous, or compound heterozygous, for SLC26A2 mutations
(Table 3). More speciﬁcally, of those 16 patients, 13 (13/15, ∼86%)
were homozygous for the common p.Arg279Trp AR-MED muta-
tion [Superti-Furga et al., 1999], while one patient was compound
heterozygous (p.Arg279Trp and IVS1+2T>C). Three other patients
were compound heterozygous, with the common “Finnish” muta-
tion (IVS1+2T>C) [Hastbacka et al., 1999] and p.Cys653Ser both
occurring twice; the remaining two mutations being p.Ala715Val
and p.Phe256Ser. The latter mutation had not been observed prior
to this study; its absence in well over 200 control samples and the
proximity to two other known pathogenic mutations (p.Gly255Glu
and p. Gly259Val) conﬁrm its putative pathogenicity.
Novel Mutations in the EGF-Like Repeats of COMP in
PSACH and MED Patients
We failed to identify COMP, MATN3, COL9A1, COL9A2,
COL9A3,o rSLC26A2 mutations in 30 patients that had originally
beenreferredtoESDNwithaworkingdiagnosisofPSACHorMED
and variants (Supp. Table S1). We therefore decided to extend the
screening of some of these patients to include exons 1–7 of COMP,
exons 3–6 of MATN3, exons 1–3 and 5–6 of MATN1, and exons 2
Table 2. Three Patients Screened for COMP Mutations that had (S)EMD or Nontypical PSACH
Patient Diagnosis on referrala Reasons why not “classical” PSACH
Alternative diagnosis suggested
prior to mutation screeningb
ESDN-00074 (S)EMD unspeciﬁed (1) Advanced carpal ossiﬁcation. (1) SEMD unspeciﬁed
(2) Flat instead of rounded vertebrae.
(3) No mini-epiphyses in the hips.
ESDN-00618 PSACH (1) Radiographic features were not severe enough in knees, hips, and spine. (1) Acromesomelic dysplasia
(2) Hand radiographs show very short and broad phalanges with
precocious ossiﬁcation of the epiphyses attached to the metaphyses.
(2) Acrocapitofemoral dysplasia
(3) CHH
ESDN-00695 PSACH (1) Vertebral bodies appeared too ﬂat for PSACH but instead resembled
those in the non-Comp pPSACH family (14).
(1) AR-PSACH
(2) pPSACH
(2) Hips and knees are reminiscent of AD PSACH. (3) SED
(3) Tubular bones in hands are not short enough and the delayed carpal
ossiﬁcation is too pronounced.
aDiagnosis as provided by the referring clinician.
bDiagnosis suggested by the ESDN panel. ESDN-00695 had previously tested negative for a COL2A1 mutation.
PSACH, pseudoachondroplasia; SED, spondyloepiphyseal dysplasia; (S)EMD, (spondylo)-epi-metaphyseal dysplasia; CHH, cartilage hair hypoplasia; AR-PSACH, autosomal
recessive PSACH; pPSACH, pseudo-PSACH.
HUMAN MUTATION, Vol. 33, No. 1, 144–157, 2012 147Figure 2. Radiographic ﬁndings in COMP negative patients referred as PSACH. ESDN-00074: Radiographs of the spine, pelvis, knees, and left
hand.Withtheexceptionofthelefthandtakenat4yearsofage,allradiographsweretakenattheageof3years.Thevertebralbodiesareﬂattened,
the proximal femoral epiphyses are small, and the femoral necks are short. The trochanters minor are well ossiﬁed and prominent present. The
knee epiphyses are small and irregularly ossiﬁed. The metaphyses in the knees are widened and the femoral distal metaphyses have spikes at
both ends. The submetaphyseal regions have a striated pattern. The hands show shortening and broadening of the metacarpals and phalanges
with small epiphyses. The epiphyses of the proximal phalanges are fragmented. There is advanced carpal ossiﬁcation with rather rectangular
(and not rounded) shape of the carpal bones. The distal ulna shows precocious ossiﬁcation of the epiphysis and cupped metaphysis. ESDN-00618:
Radiographsofspine,pelvis,knee,andhandtakenattheageof6months.Thepelvisisabnormalwithﬂatandtridentacetabularroofandsmalland
broad iliac wings. The ischiadic bones are broad. The proximal femoral epiphyses are well ossiﬁed for age. The femoral necks appear broad. The
handshowsshorteningofphalangesandmetacarpals,especiallytheproximalandmiddlephalangesareveryshortwithpoordiaphysealmodeling
and precocious ossiﬁcation of the epiphyses that are attached to the metaphysis. The vertebral bodies are mildly foreshortened with posterior
scalloping.Nogrossabnormalities areseenattheknee.ESDN-00695:Radiographs ofspine,pelvis,knee,andhandtakenattheageof7years.The
mini-epiphyses in the hips and the small epiphyses in the knees with translucent submetaphyseal areas in the proximal tibia are reminiscent of
PSACH. However, the hand shows only mild shortening of the phalanges and metacarpals. In addition, there is marked delay in carpal ossiﬁcation.
The epiphyses in the wrist and hands are too small for age. The vertebral bodies are ﬂattened and elongated.
and 6+7o fMATN4 (Supp. Table S1). We speciﬁcally chose these
exons because they encode important structural and/or functional
domainsinglycoproteinsthatarestructuralcomponentsofthecar-
tilage growth plate. For example, the EGF-like repeats of COMP
and MATN3 and the EGF-like and A-domains of matrilin-1 and
-4 are important for protein integrity and interactions in cartilage
[Wagener et al., 2005]. Moreover, mutations in the ﬁrst EGF-like
repeat of MATN3 had been reported to cause recessive spondylo-
epi-metaphyseal dysplasia (SEMD, MATN3 related) [Borochowitz
et al., 2004] and confer susceptibility to hand osteoarthritis
[Stefansson et al., 2003].
In one patient with MED and in the one remaining patient with
“classical” PSACH, we identiﬁed novel mutations in exons 5 and
7o fCOMP, respectively (Table 5; Fig. 3). MED patient ESDN-
00521 was heterozygous for c.500G>A, which is predicted to result
in a p.Gly167Glu substitution in the second EGF-like repeat of
COMP. In PSACH patient ESDN-01040, we identiﬁed a heterozy-
gous c.700C>T, which resulted in a p.Pro234Ser substitution in the
fourth EGF-like repeat of COMP; both of these unclassiﬁed vari-
ants had not previously been reported and were not present in the
dbSNP database version 130 (May 2009). In contrast, no mutations
were identiﬁed in the additional exons of MATN1, MATN3,a n d
MATN4 that we screened, which is consistent with our previous
studies [Jackson et al., 2004].
Novel Mutations in Exon 50 of COL2A1
Finally,weextendedourscreeningtoincludeexon50ofCOL2A1
since a recurrent mutation (p.Gly1170Ser) in this exon has been
shown to cause Legg-Calve-Perthes (LCP) disease in four fami-
lies [Miyamoto et al., 2007; Su et al., 2008], and there is clear
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HUMAN MUTATION, Vol. 33, No. 1, 144–157, 2012 151Table 4. Two MED Patients with Multiple Mutations Identiﬁed in COMP and MATN3
ESDN 00359 Clinical status COMP screening
Proband MED c.1206T>C
c.1502G>A
c.1504G>T
Father of proband Unaffected None detected
Mother of proband Affected c.1206T>C
c.1502G>A
c.1504G>T
Sister of proband Unknown None detected
ESDN 00594 Clinical status COL9 screening MATN3 screening COMP screening
Proband MED None detected c.733G>A,p.Val245Met c.1502G>A,p.Gly501Asp
c.2267A>G,p.Gln756Arg
c.2274+1G>C
Father of proband MED or mild PSACH n/a c.733G>A,p.Val245Met c.1502G>A,p.Gly501Asp
c.2267A>G,p.Gln756Arg
c.2274+1G>C
Patient ESDN-00359 was shown to be heterozygous for three COMP variants, which were all inherited from his affected father and therefore co-segregated as a single haplotype.
Patient ESDN-00594 inherited three COMP variants and a single MATN3 variant from his affected father. Nucleotide numbering according to cDNA sequence with nucleotide 1
counted as the ﬁrst nucleotide of the translation initiation codon. GenBank accession numbers NM_000095.2 (COMP); NM_002381.4 (MATN3).
Table 5. Novel COMP and COL2A1 Mutations Identiﬁed in Four Patients with Clinically and Radiographically Conﬁrmed PSACH or MED
Patient Phenotype Gene Exon Nucleotide change Protein change Domain Proof of pathogenicity
ESDN-00521 MED COMP 5 c.500G>A p.Gly167Glu EGF-like 2 Evolutionally conserved functional residues in type II repeats of
ESDN-01040 PSACH COMP 7 c.700C>T p.Pro234Ser EGF-like 4 COMP and not present in 20 other PSACH-MED patients
ESDN-00050 MED COL2A1 50 c.3535G>A p.Gly1179Arg Triple helical region Highly conserved glycine residues vital for correct triple helical
ESDN-00283 MED COL2A1 50 c.3527G>T p.Gly1176Val Triple helical region formation. Mutations in neighboring glycine residues,
p.Gly1173Arg and p.Gly1176Ser, shown to be pathogenic
COMP EGF-like mutations were identiﬁed in MED patient ESDN-00521 and PSACH patient ESDN-01040, both of which are novel variants that are not present in the dbSNP
database version 130 (May 2009). COL2A1 mutations identiﬁed in two MED patients (ESDN-00050 and -00283) that affected conserved glycine residues in the triple helical
region of type II collagen. Nucleotide numbering according to cDNA sequence with nucleotide 1 counted as the ﬁrst nucleotide of the translation initiation codon. GenBank
accession numbers NM_000095.2 (COMP); NM_001844.4 (COL2A1).
clinical overlap between LCP and MED [Herring and Hotchkiss,
1987; Ikegawa et al., 1991]. Patient ESDN-00050 (mild MED) was
heterozygous for c.3535G>A, which is predicted to result in a
p.Gly1179Arg substitution and patient ESDN-00283 (MED) was
heterozygous for c.3527G>T, which is predicted to result in a
p.Gly1176Val substitution (Table 5).
Discussion
In this study, we undertook a comprehensive clinical and molec-
ular approach to deﬁne the genetic basis of PSACH and MED in
a cohort of 130 patients referred to ESDN. All of these patients
had been referred to ESDN between 2003 and 2010 with various
working diagnoses of PSACH (27); PSACH-MED (3); MED (66)
(including variants described as Fairbank (2), polyepiphyseal dys-
plasia (1), MED with sacroiliitis (1), MED with neuropathy (1) and
Perthes (2)); rMED (9); spondyloepiphyseal dysplasia (SED)/MED
(1); SED (4); SEMD (2) (including a variant described as SEMD-JL
[1]); SMD (1); PPRD (2); mild DTD (3), or without any formal
diagnosis (4).
For the vast majority of patients referred to ESDN with a provi-
sional diagnosis of PSACH, the panel agreed with the diagnosis and
a COMP mutation was subsequently found (Table 1). This obser-
vation implies that PSACH is relatively straightforward to diagnose
givensuitableradiographsandclinicalsummary,however,itshould
benotedthatatleast21ofthe27PSACHreferralscamefromgeneti-
cists within clinical genetics departments, including eight referrals
from members of the ESDN panel, suggesting that the cases came
from clinicians with experience in skeletal dysplasias. The three ex-
ceptions were ESDN-00074, ESDN-00618, and ESDN-00695, but
atypical clinical and radiographic features excluded PSACH and
suggested an alternative diagnosis prior to sequencing the COMP
gene (Table 2; Fig. 2).
In the other 56 patients in whom we identiﬁed a COMP, MATN3
or type IX collagen gene mutation, the majority had been referred
to ESDN with a diagnosis of MED (Table 3), which would indicate
that the “classical” forms of MED (i.e., those patients in whom
we identiﬁed a mutation) are also relatively easy to diagnose. This
was particularly the case for those patients in whom we identiﬁed
MATN3,COL9A2,orCOL9A3mutations[i.e.,18/19(94%)patients
withthesemutationshadacorrectdiagnosisuponreferraltoESDN;
seeTable3].Onceagainthesereferralscamealmostexclusivelyfrom
geneticists within clinical genetics and/or pediatrics departments
and included nine referrals from members of the ESDN panel.
Finally, in those patients in which we identiﬁed a DTDST muta-
tion, 69% (11/16 patients) had originally been referred with a diag-
nosis ofMEDorrMED;withPPRD(2)andmildDTD/SED/SEMD
(3) being proposed as a diagnosis in ﬁve cases. This observation
would therefore suggest that rMED is slightly harder to diagnose
than classical AD-MED. This may be explained partly by the fact
that unlike AD-MED where family history is often positive, most
cases of rMED lack a family history and therefore physicians may
be less inclined to think of a possible genetic cause of the disorder.
Likewise, all the referrals came from geneticists within clinical ge-
netics departments and also included three referrals from members
of the ESDN panel.
152 HUMAN MUTATION, Vol. 33, No. 1, 144–157, 2012Figure3. RadiographicﬁndingsinPSACHandMEDpatientswithmutationsidentiﬁedintheEGF-likerepeatsofCOMP.ESDN-00521:Radiographs
taken at the age of 6 years. The proximal femoral epiphyses are small and ﬂattened. The distal femoral and proximal tibial epiphyses are also small
for age. There is no ossiﬁcation yet of the proximal ﬁbular epiphysis. The hand radiograph shows normal phalanges and metacarpals but delayed
ossiﬁcation of the carpal bones and epiphyses in the wrist. The spine is normal. ESDN-1040: The radiographs of pelvis and knee taken at the age
of 6 years shows very small epiphyses in the hips and knees, which is reminiscent of pseudoachondroplasia. Note, also the two round translucent
areas in the distal femoral metaphysis, which are often seen in patients with pseudoachondroplasia.
Inspiteofthediagnosticdifﬁculties,we canconﬁrmthatautoso-
mal recessive MED (rMED) accounts for approximately one-fourth
of total MED cases, as has been suggested by earlier studies (15, 16).
This relatively high incidence is driven by the frequency of the
p.R279W mutation, which is by far the most common DTDST mu-
tation in the European population [Ballhausen et al., 2003; Barbosa
etal.,2010;RossiandSuperti-Furga,2001].Interestingly,ithasbeen
reportedthatDTDSTmutationsarenotacommoncauseofMEDin
some Asian populations [Itoh et al., 2006]. On the whole, this study
suggests that ESDN receives a signiﬁcant number of referrals from
geneticists and/or pediatricians with an interest in, and knowledge
of, skeletal dysplasias, which is reﬂected in the relatively high level
of correct diagnosis on referral.
The range of COMP mutations that we identiﬁed in the PSACH
patients was similar to those previously published [Kennedy et al.,
2005a]andincludedmissensemutationsthatresultedinthesubsti-
tution of conserved glycine, aspartic acid, asparagine, and cysteine
residues, which are important for the folding, structural integrity,
andcalciumbindingofthetypeIIIrepeats[Tanetal.,2009].Wealso
identiﬁedthecommonp.Asp473delmutationinsixPSACHpatients
and more complex deletions in three other patients, thus in-frame
deletions were identiﬁed in approximately 33% of PSACH patients
(9/27), which was slightly less than the 43% that we have previously
reported[Kennedyetal.,2005a].TherangeofCOMPmutationsthat
weidentiﬁedintheMEDpatientswasmorediversethanthosefound
in PSACH and in addition to the substitution of conserved glycine,
aspartic acid, asparagine, and cysteine residues, we also identiﬁed
missense mutations that resulted in the substitution of noncon-
servedproline(p.Pro276Arg)andserine(p.Ser298Leu)residuesand
aconservedalanine(p.Ala311Asp)residueallwithinthelinkerorthe
T31 repeat of the Type III region (Fig. 4). We also identiﬁed a broad
rangeofin-framedeletion,duplication,anddeletion/insertionmu-
tationsincludingthepreviouslyreportedp.Asp473dup[Delotetal.,
1999]. It is an interesting observation that p.Asp473del consistently
causesPSACH,whilep.Asp473dupalwayscausesMED.Presumably,
the insertion of a aspartic acid reside into the C-type motif of T36 is
less deleterious to protein folding and structure than its deletion.
Interestingly, we identiﬁed the recurrent p.Asn523Lys
(c.1569C>G) mutation in three MED patients from our panel
(ESDN-00123, 00382, and 00751), all of whom were from the
Netherlands. Furthermore, this same mutation was previously
identiﬁed in a large South African kindred of Dutch descent [Ballo
et al., 1997], suggesting that this is an ancestral mutation. We also
identiﬁed therecurrent p.Asp385Asn(c.1153G>A) mutation in two
British and one Dutch family with MED (ESDN-00049, 00509, and
00597), in addition to p.Asp585Asn and p.Asp385del mutations,
which points to a key role for Asp385 in the structure of COMP.
Finally, when just considering the 34 different COMP missense
mutations that we identiﬁed in the type III region, sequence align-
ments reveal that 85% (29/34) of them affect residues in the C-type
motifofthelinkerandT31–7 repeats(Fig.4).Thissuggeststhatcon-
served residues in this motif are more important for coordinating
calcium binding and/or the folding of COMP; the ﬁve mutations
that we identiﬁed in the N-type motif all cause MED.
Mutations in exons 14–18 of COMP, which encodes the C-
terminal domain were identiﬁed in approximately 13% (8/64) of
PSACH and MED patients and were once again clustered at spe-
ciﬁc residues as previously noted [Kennedy et al., 2005b]. These
observationsreinforcethehypothesisthatThr529,Thr585,Arg718,
and Gly719 are important for the structure and/or function of the
HUMAN MUTATION, Vol. 33, No. 1, 144–157, 2012 153Figure 4. Localization of COMP mutations identiﬁed in PSACH and MED patients in this study. An amino acid sequence alignment of the type III
repeatsregionofCOMP,withthelinkerregionandeachofthesevenT3repeats(T31−7)shownwiththeircorrespondingresiduenumbers.Residues
comprising the N-type and C-type motif are boxed and the consensus sequence of each motif is indicated below. Also shown on the alignment are
the missense mutations that cause either MED (∗), PSACH (ˆ), or both (+) phenotypes. In-frame deletions are underlined.
C-terminal domain of COMP. Indeed, we have now identiﬁed ev-
ery possible amino acid substitution of Thr585 [i.e., pThr585Met,
p.Thr585Lys(unpublisheddata),andp.Thr585Arg],whichallresult
from either a transversion or transition at nucleotide c.1754, sug-
gesting that this nucleotide is particularly susceptible to mutation,
but also conﬁrming that methionine at residue 585 is vital for the
correct folding and/or functioning of COMP.
MED mutations in MATN3 were again found in exon 2, which
encodes the single A-domain of MATN3 and affected residues in
either the β-stands (70%) or α-helices (30%). The identiﬁcation of
an in-frame deletion/insertion (c.513_530del), which is predicted
to result in a p.Asp171_Glu177delinsGlu in the α4 helix, is the ﬁrst
mutationofthiskindtobeidentiﬁedinMATN3andthusextendsthe
type of mutations in MATN3 that can cause MED. The clustering of
mutations in exon 2 demonstrates the importance of the A-domain
and most studies have demonstrated that these mutations disrupt
the folding of this domain [Cotterill et al., 2005], which elicits and
unfolded protein response [Nundlall et al., 2010].
Interestingly, in all six patients in whom we identiﬁed a COL9
mutation, the ESDN panel had predicted or suggested a type IX
collagen defect prior to mutation screening. The ability of the panel
toaccuratelypredictaCOL9mutationwasaresultofthepreviously
documented differences in the clinical and radiographic presenta-
tion of MED caused by a type IX collagen mutation compared to
COMP and MATN3 mutations [Lachman et al., 2005; Unger et al.,
2008, 2001]. COL9-MED is generally the mildest form of MED and
is characterized by joint pain and stiffness presenting in the ﬁrst
decade of life, while radiographic abnormalities are primarily re-
stricted to the knees with relative sparing of the hips. Interestingly,
three of the six patients (ESDN-0638, 0926, and 0997) were from
the Netherlands and two of these shared the same c.186+2C>Tm u -
tation in COL9A2, which was originally identiﬁed in a large Dutch
kindred in 1986 [Muragaki et al., 1996; van Mourik et al., 1998]
and more recently in a second large family of Dutch origin [Jackson
et al., 2010; Versteylen et al., 1988]. These data might suggest that
the c.186+2t>c mutation in COL9A2 is another ancestral mutation
in the Dutch population; however, haplotype analysis should be
performed to test this hypothesis further. In contrast, three British
familieswithCOL9A2-MEDallhadadifferentmutation;c.186+4a>c
(ESDN-01003 in this study), c.186+5g>c [Holden et al., 1999], and
c.186+6t>g [Barrie et al., 1958; Briggs et al., 1994; Spayde et al.,
2000]. Finally, although it has been proposed that COL9-MED mu-
tationsaremoreprevalentinJapan[Itohetal.,2006],itisinteresting
to note that of the 14 COL9A2 mutations published to date, 12 have
actually been identiﬁed in families from Northern Europe (UK [3],
Netherlands [4], Germany [2], Sweden [1], and unspeciﬁed [1]).
O u rs t u d yh a sn o wd e m o n s t r a t e dt h a tm u t a t i o n si nCOL9A2 and
COL9A3 account for approximately 10% of mutations in molecu-
larlyconﬁrmedMED,whichisslightlylessthanthe16%reportedby
Itohandcolleagues[Itohetal.,2006].Incontrast,COMPmutations
accounted for 66% of mutations (37% in [Itoh et al., 2006]) and
MATN3 for 24% of mutations (47% in [Itoh et al., 2006]). These
differencesintherelativeproportionsofCOMP,MATN3,andCOL9
mutations may be due to ascertainment bias or ethnic differences.
The panel’s success in predicting a COL9 mutation was not re-
peated with MED resulting from MATN3 mutations and in most
cases the panel could not decide between COMP or MATN3 as the
causative gene prior to screening (although the COL9 genes were
never considered as candidates). These observations would suggest
that there are phenotypic features (both clinical and radiographic)
shared between COMP-MED and MATN3-MED, which may result
fromcommondiseasemechanisms.Indeed,recentstudiesofknock-
in mouse models of mild PSACH and MED caused by Comp and
Matn3 mutations, respectively, suggest that speciﬁc characteristics
of growth plate pathophysiology, such as reduced chondrocyte pro-
liferation and increased and/or spatially dysregulated apoptosis are
common disease mechanisms [Leighton et al., 2007; Pirog-Garcia
et al., 2007].
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tiﬁedmorethanonepotentialmutationthatco-segregatedwiththe
phenotype following family studies (Table 4). MED patient ESDN-
00359 had three changes identiﬁed in COMP; p.Gly404Gly (a non-
pathogenicneutralpolymorphism),p.Gly501Asp,andp.Asp502Tyr,
which are both conserved amino acid residues in the N-type motif
of the T37 repeat and help to co-ordinate Ca2+ binding. All three
changes co-segregate as a single haplotype since they were also
present in the suspected affected mother, but not the unaffected
father, of the proband. In this case, it would seem most likely that
a single mutational event affecting contiguous nucleotides in the
codons of both Gly501 (GGC) and Asp 502 (GAC) would account
forthesetwomutations(p.Gly501Aspandp.Asp502Tyr).Bothmu-
tations might conceivably cause MED on their own by affecting
highly conserved amino acids important for protein folding and
calcium binding, respectively.
ESDN-00594 had four changes; three in COMP and a single
change in MATN3,n o n eo fw h i c hh a v ep r e v i o u s l yb e e nr e p o r t e d
(Table 4). The COMP changes included p.Gly501Asp (also iden-
tiﬁed in ESDN-00359 and ESDN-00422); p.Gln756Arg, which is
at the end of the C-terminal domain of COMP (and interestingly
arginine is present at that same position in bovine and rat COMP);
and ﬁnally c.2274+1G>C which is in the 3  untranslated region and
might affect mRNA stability leading to reduced protein levels, but
since COMP-null mice are normal, this change is unlikely to have a
phenotypic effect. The MATN3 mutation is at a conserved residue
(p.Val245)intheαFstrandoftheMATN3A-domainandfunctional
studies show p.Val245Met affects to some extent the trafﬁcking and
secretion of MATN3 A-domain [unpublished data]. Importantly,
the p.Gly501Asp mutation in ESDN-00422 was recently conﬁrmed
as de novo in this family [Stephen Robertson, personal communi-
cation], conﬁrming that it is the cause of MED in ESDN-00594.
Nevertheless, the intracellular retention of a signiﬁcant proportion
of p.Val245Met suggests the intriguing possibility that it might be a
genetic modiﬁer of phenotypic severity.
By extending our standard screening protocol, we identiﬁed mu-
tationsinCOMPandCOL2A1intheremainingPSACHpatientand
in three MED patients. In PSACH patient ESDN-01040, we identi-
ﬁed a heterozygous p.Pro234Ser substitution in the fourth EGF-like
repeat of COMP and MED patient ESDN-00521 was heterozygous
for p.Gly167Glu in the second EGF-like repeat of COMP. Both of
these residues are conserved in murine COMP and the substitution
of glycine and proline residues in the EGF-like repeats of ﬁbrilin-1
has been shown to cause Marfan Syndrome [Arbustini et al., 2005;
Collod-Beroudetal.,1999].Morerecently,wehaveidentiﬁedathird
COMP EGF-like mutation in a patient with PSACH, p.Gly258Arg,
which is in the fourth repeat and again conserved across species
(unpublisheddata),butthepreciseaffectoftheseCOMPmutations
remains undetermined and will require extensive studies in vitro.
Both of the COL2A1 mutations that we identiﬁed (p.Gly1176Val
and p.Gly1179Arg) were in suspected MED patients (ESDN-00283
and ESDN-00050) in whom there was limited clinical information
andradiographicimagesinwhichtomakeanunambiguousdiagno-
sis (Table 5). However, in both cases while there were some features
consistent with MED, it was also noted that there were features not
normally associated with MED such as short trunk and severely
fragmented hip epiphyses with adjacent metaphyseal anomalies.
This observation would suggest that there is some clinical and ra-
diographicoverlapbetweenMEDandmildSEDcongenital(SEDc),
which is borneoutby thefact thatsimilar mutations,p.Gly1173Arg
[Sobetzkoetal.,2000]andp.Gly1176Ser[Williamsetal.,1995],have
previouslybeenshowntocauseSEDctype.Furthermore,theidenti-
ﬁcationofarecurrentp.Gly1170SermutationinpatientswithLegg-
Calve-Perthes disease (LCPD) and/or primary avascular necrosis of
femoral head (ANFH) [Miyamoto et al., 2007; Su et al., 2008] also
suggests that there are similar disease mechanisms that might cause
phenotypes within a LCPD/ANFH-MED-SEDc disease spectrum.
Finally, in those patients in whom we could not identify a muta-
tion in the core exons of our screening protocol, the predominant
diagnosisonreferralhadbeenMEDorrMED(Supp.TableS1:22/30
[80%]), with the remainder being PSACH (1), DTD (2), SED (3),
or unknown (2). This observation would suggest that the mutation
negative cases of MED are due to either a mutation in an as yet
unknown gene(s), or the diagnosis of MED was incorrect in these
patients. Interestingly, on re-review of these cases it was clear that
theESDNpanelhadnotagreeduponaconsensusdiagnosisformost
of these cases. Indeed, there were only two mutation negative pa-
tientsinwhichadiagnosisofsuspectedmildMEDwasagreedupon
by the panel prior to screening (Supp. Table S1; ESDN-00039 and
ESDN-00160).Inthemajorityofcasesinwhichwedidnotidentifya
mutationinthisstudy(Supp.TableS1:24/26[96%]),analternative
diagnosis was suggested prior to mutation screening and for many
casesthiswaseitherMeyer’sdisease/hipdysplasia(Beukes)/bilateral
LCPD (8/26), a type II collagenopathy (5/26), or SEMD (2). This
wouldsuggestthatthereareformsoffamilialhipdysplasia,variably
described in the literature as Meyer’s disease (dysplasia epiphysealis
capitisfemoris),familialhipdysplasia(Beukes),andbilateralLCPD,
that are genetically distinct from the classical forms of MED and do
not result from mutations in COMP, MATN3,o rt y p eI Xc o l l a g e n .
The genetic cause of these diseases remains underdetermined, but
the careful use exome sequencing may help identify potential can-
didate genes. Finally, it is interesting to note that like the mutation
positive cases, the majority of mutation negative patients had also
been referred by geneticists within clinical genetics departments in-
cluding six from members of the ESDN panel. This would indicate
that in these patients there are clear difﬁculties in making a correct
diagnosis rather than a lack of relevant expertise.
In summary, we have shown that in the context of PSACH and
theMEDdiseasespectrum,theclassicalformofPSACHisrelatively
straightforward to diagnose provided there is sufﬁcient clinical and
radiographic information. In cases of PSACH, a COMP mutation
should be identiﬁed, however, we have additional evidence to con-
ﬁrm that a PSACH-like phenotype is distinct from classical PSACH
and does not result from a COMP mutation [Spranger et al., 2005].
In contrast, the radiographic signs of MED are more subtle and
variable, and while the ESDN panel was relatively successful in pre-
dicting genotype from the phenotype, MED remains more difﬁcult
todiagnosecorrectly.Ourstudyconﬁrmsthataccuratereviewbyan
expert panel may help in prioritizing the genes to be sequenced and
thus reduce both time and cost. Those cases that remain “mutation
negative” should be carefully re-reviewed and alternative diagnoses
possibly considered. Finally, our comprehensive study also throws
doubtonpreviousstudiesthathave suggestedthatmutationsinthe
known genes are not the major cause of MED [Jakkula et al., 2005],
and we conclude that mutations in COMP, MATN3,a n dt y p eI X
collagen genes account for the vast majority of classical AD-MED.
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